Short answer
Dyne Therapeutics, Inc. (DYN) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$108M
- −11.2% YoY · +2.5% QoQ
- EPS (diluted)
- −$0.72
- +26.5% YoY · +25.8% QoQ
Source: XBRL data from the Dyne Therapeutics, Inc. (DYN) Q3 2025 10-Q on SEC EDGAR. USD.
Dyne Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Operating loss $113.9M vs $105.7M YoY; operating margin not applicable
- Research and development expense $97.2M vs $92.8M YoY
- Cash resources expected to fund operations into third quarter 2027
- Registrational expansion cohort enrollment planned for early second quarter 2026; Phase 3 z-basivarsen trial planned first quarter 2026
Risk Factors
- Net losses $334.3 million for nine months ended September 30, 2025, versus $227.9 million in 2024
- Cash resources $791.9 million, expected to fund operations into third quarter 2027 under stated assumptions
- Hercules Loan Agreement added $100.0 million initial borrowing and up to $175.0 million additional, subject to milestones and approval
- Minimum Cash Covenant begins April 1, 2026, initially requiring cash equal to 60% of outstanding obligations
- FDA clinical-development risk: prior z-rostudirsen IND clinical hold required additional clinical and non-clinical information
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dyne Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.